Abstract
Relapsed/refractory acute myeloid leukemia (R/R-AML) has a poor prognosis. CD7 is expressed in leukemic cells in 30% of patients with AML but not in normal myeloid cells. Therefore, it can be a potential target for immunotherapy in patients with R/R-AML. Naturally selected CD7-directed chimeric antigen receptor T cells (CAR-T) have promising effects against AML based on xenotransplantation models. We report a R/R-AML case that achieved complete remission with incomplete hematologic recovery with naturally selected CD7 CAR-T therapy. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) as consolidation early after CAR T therapy, the patient experienced 12 months of disease-free survival to date. Our results confirmed that allogeneic hematopoietic stem cell transplantation after naturally selected CD7 CAR-T therapy can be a potential treatment for patients with CD7-positive R/R-AML.
Introduction
Relapsed or refractory acute myeloid leukemia (R/R-AML) remains a significant clinical challenge, with median survival often limited to approximately one year. While allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a curative pathway, its success is contingent upon achieving complete remission (CR) prior to the procedure—a state frequently unattainable through conventional salvage chemotherapy.
The surface protein CD7 is expressed in roughly 30% of AML cases but is absent in normal myeloid lineages, identifying it as a viable target for chimeric antigen receptor (CAR) T-cell therapy. However, the development of CD7-directed CAR-T cells is complicated by "fratricide," where the engineered T cells target one another due to endogenous CD7 expression. This study explores a "natural selection" approach to bypass this hurdle, using CAR-T therapy as a bridge to definitive allo-HSCT.
Methods
The study details the treatment of a 48-year-old female with CD7-positive R/R-AML who had failed multiple chemotherapy regimens.
NS7CAR Production
To avoid complex gene editing (e.g., CRISPR/Cas9) to eliminate CD7 expression, researchers employed a "naturally selected" CAR-T (NS7CAR) method. T cells were transduced with a CD7-directed CAR; through intracellular sequestration or antigen masking, a subset of cells naturally avoided self-destruction. These surviving cells were expanded for clinical use.
Clinical Protocol
The patient received lymphodepleting chemotherapy followed by NS7CAR-T infusion. Upon achieving remission, the patient underwent a haplo-matched allo-HSCT from her daughter. Monitoring included CAR-T expansion via DNA quantification, cytokine profiling (IL-6, IL-10) for Cytokine Release Syndrome (CRS) management, and flow cytometry for Minimal Residual Disease (MRD) assessment.
Results
The patient demonstrated a rapid response to the NS7CAR-T infusion. Bone marrow blasts decreased from 28.5% to less than 5% within 14 days, achieving MRD negativity.
Toxicity was manageable, with only Grade 1 CRS (transient fever) and no observed neurotoxicity (ICANS). Following the bridge to allo-HSCT, the patient achieved full donor chimerism (97.5%) and has remained in disease-free survival for 12 months. A post-transplant complication of thrombotic microangiopathy (TMA) was successfully resolved with defibrotide and immunosuppressant adjustment.
Discussion
This case highlights the potential of CD7-directed CAR-T cells as a potent "debulking" agent to facilitate successful transplantation in refractory AML. The "natural selection" manufacturing process offers a streamlined alternative to gene-edited products, potentially lowering the barrier to entry for this therapy.
However, the occurrence of post-transplant TMA raises questions regarding whether prior CAR-T therapy might sensitize the endothelium to subsequent transplant-related injury. Further large-scale trials are necessary to validate the safety and long-term efficacy of this bridging strategy and to determine if CAR-T persistence could eventually allow for standalone therapy in AML.
Conclusion
Naturally selected CD7 CAR-T therapy followed by early consolidation with allo-HSCT represents a promising therapeutic strategy for CD7-positive R/R-AML, offering a path to long-term remission in a high-risk patient population.
Summary updated